Literature DB >> 22186246

Efficacy of using a hydrodebrider and of citric acid/zwitterionic surfactant on a Staphylococcus aureus bacterial biofilm in the sheep model of rhinosinusitis.

Rowan Valentine1, Josh Jervis-Bardy, Alkis Psaltis, Lor Wai Tan, Peter-John Wormald.   

Abstract

BACKGROUND: Biofilms in chronic rhinosinusitis (CRS) patients are associated with recalcitrant disease patterns. Citric acid/zwitterionic surfactant (CAZS) has been shown to have significant efficacy at in vitro biofilm eradication. Unique hydrodebrider systems have been shown to have effective antibiofilm efficacy. The aim of this study was to evaluate the efficacy of the CAZS/hydrodebrider treatment on Staphylococcus aureus biofilms in the sheep model of CRS.
METHODS: Forty-two sheep frontal sinuses were inoculated with S. aureus, followed by 7 days of biofilm growth. Sinuses were randomized to one of nine treatment groups: control, hydrodebrider with saline or CAZS (killed on day 0 or day 7 posttreatment), CAZS, or saline flush (killed on day 0 or day 7 posttreatment). Confocal scanning laser microscopy (CSLM) was used to confirm extent of biofilm reduction. Samples of each sinus were taken, assessing cilia morphology using electron microscopy.
RESULTS: A mean of 37.22 ± 9.65% of control (no treatment) CSLM images taken showed biofilms. Both CAZS flush and CAZS/hydrodebrider treatments showed initial improvements in biofilms but biofilm regrowth followed treatment, 14.74 ± 9.58% to 18.91 ± 12.14% and 15.60 ± 13.92% to 24.70 ± 3.66%, respectively (p > 0.05). Saline/hydrodebrider treatments showed a nonsignificant improvement in biofilm treatment, which was maintained, 18.34 ± 11.85% to 12.04 ± 10.28% (p > 0.05). Cilial morphology grade was significantly worse in the CAZS treatment groups (p < 0.05).
CONCLUSION: CAZS solution (with and without a hydrodebrider system) can significantly adversely affect cilia morphology. The hydrodebrider system, when combined with saline, may be a useful treatment adjunct for mucosal biofilms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22186246     DOI: 10.2500/ajra.2011.25.3659

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  7 in total

Review 1.  Update on Intranasal Medications in Rhinosinusitis.

Authors:  Kornkiat Snidvongs; Sanguansak Thanaviratananich
Journal:  Curr Allergy Asthma Rep       Date:  2017-07       Impact factor: 4.806

Review 2.  Topical Antibiofilm Agents With Potential Utility in the Treatment of Chronic Rhinosinusitis: A Narrative Review.

Authors:  Samuel J M Hale; Brett Wagner Mackenzie; Christian A Lux; Kristi Biswas; Raymond Kim; Richard G Douglas
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

Review 3.  Surfactants in the management of rhinopathologies.

Authors:  Philip L Rosen; James N Palmer; Bert W O'Malley; Noam A Cohen
Journal:  Am J Rhinol Allergy       Date:  2013 May-Jun       Impact factor: 2.467

4.  Chronic rhinosinusitis and antibiotics: the good, the bad, and the ugly.

Authors:  Joshua L Kennedy; Larry Borish
Journal:  Am J Rhinol Allergy       Date:  2013 Nov-Dec       Impact factor: 2.467

5.  Efficacy of citric acid denture cleanser on the Candida albicans biofilm formed on poly(methyl methacrylate): effects on residual biofilm and recolonization process.

Authors:  Fernanda Faot; Yuri Wanderley Cavalcanti; Martinna de Mendonça e Bertolini; Luciana de Rezende Pinto; Wander José da Silva; Altair Antoninha Del Bel Cury
Journal:  BMC Oral Health       Date:  2014-06-23       Impact factor: 2.757

6.  Middle ear irrigation using a hydrodebrider decreases biofilm surface area in an animal model of otitis media.

Authors:  Ralph Abi Hachem; Stefania Goncalves; Thomas Walker; Simon Angeli
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-05-25

7.  Two Cases of Allergic Fungal Sinusitis with Differing Postoperative Course.

Authors:  Yuma Matsumoto; Hidenori Yokoi; Michitsugu Kawada; Masachika Fujiwara; Koichiro Saito
Journal:  Case Rep Otolaryngol       Date:  2019-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.